Tag Archives: biotechnology news

Patenting “Natural Products” Down-Under Post-Myriad

Although the Australian High Court held that claims to naturally occurring DNA (e.g., BRCA1 nucleic acid) were not patent eligible because they were not a “manner of manufacture,” since the encoded information therein was not “made” by human action, in … Continue reading

Posted in Non-U.S. Practice | Tagged , , , , , , , , | 1 Comment

USPTO Report on State of Confirmatory Genetic Testing Comes off the Waffle Iron

In 2011—after the Fed. Cir. decision in Myriad upholding claims to BRACA1 and 2 genes—the PTO was tasked by a section of the AIA with providing Congress with a report on the effect of patenting on confirmatory genetic testing. The … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | Leave a comment

Physiology/Medicine Nobels Awarded for Discoveries of “Natural Products”

In re Roslin Institute, a Fed. Cir. panel consisting of Judges Dyk, Moore and Wallach ruled that clones including Dolly the sheep were not patent eligible. Judge Dyk, writing for the panel endorsed the “markedly different” structure requirement for patent eligibility … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , | 1 Comment

Shire v. Amneal Pharma – Adjusting the Rearview Mirror

While the IP law world is being rocked by new developments in biosimilars, patent-eligible subject matter and IPR’s, it is almost refreshing to see a decision upholding the validity of claims to a “small molecule” drug based on application of … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 1 Comment